Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer Authors: Prashant Changoer, Chunying Peng, Pepijn van Houten, Liesbeth van Emst, Janneke E W Walraven, Petronella B Ottevanger, Martin Jaeger, Romana T Netea-Maier Published: 2025 ABSTRACT AbstractIntroductionTyrosine kinase inhibitors, including lenvatinib approved for advanced non-medullary thyroid cancer (TC), affect the immune system. As tumor-related inflammation contributes to TC pathogenesis, this study assesses the immunomodulatory effects of lenvatinib, focusing on myeloid cells.MethodsPeripheral blood was collected from 16 lenvatinib-treated and 15 untreated TC patients (cross-sectional cohort), and from eight patients before and after > 1 month of lenvatinib (longitudinal cohort). Immune profiling included cell subset counts, proteomic analyses, and ex vivo cytokine assays in peripheral blood mononuclear cells (PBMCs) and monocytes. Monocytes from healthy donors were used to evaluate metabolic activity, reactive oxygen species (ROS) production, and phagocytosis. Tumor-intrinsic effects of lenvatinib were studied by proteomics and immunophenotyping of the TPC-1 cell line.ResultsLenvatinib increased lymphocytes and reduced neutrophils. In both cohorts, lenvatinib modulated the inflammatory proteome with elevated VEGFA, CCL11, MMP-10, and TRAIL. Monocytes exposed ex vivo to lenvatinib showed reduced production of IL-1β, IL-6, IL-8, and IL-10. In patients treated with lenvatinib, monocytes displayed increased IL-1Ra and TNF, while PBMCs exhibited enhanced IFN-γ production. Monocytes from healthy donors displayed reduced glycolysis and increased ROS after lenvatinib exposure. In TPC-1 cells, lenvatinib altered the secretome and upregulated MHC class I, PD-L1, and CD40.ConclusionsLenvatinib treatment has broad immunomodulatory effects in patients with TC, including shifts in immune cell populations, changes in the proteome, and reprogramming of cytokine responses. Lenvatinib also impacts monocyte metabolism and tumor cell phenotype. These findings provide insight into the multifaceted immunological activities of lenvatinib and highlight opportunities for treatment strategies.Trial registrationNot applicable, this is a noninterventional trial.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00262-025-04241-7.Keywords: Non-medullary thyroid carcinoma, Lenvatinib, Immunomodulation, Circulatory biomarkers, Macrophages, Monocytes Introduction Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) 1–3, fibroblast growth factor receptors (FGFR) 1–4, platelet-derived growth factor receptor α (PDGFR α), RET, and KIT [1]. Based on an increase in progression-free survival (PFS) observed in the SELECT trial, lenvatinib was approved for clinical use in the treatment of progressive non-medullary thyroid carcinoma (TC) unresponsive to the conventional treatment by surgery and radioactive iodine [2]. While lenvatinib arguably has high initial response rates, complete remissions are rare. Tumor cells often develop resistance to lenvatinib, which can arise through activation of alternative receptor tyrosine kinases (e.g., TRK, MET), activation of downstream signaling pathways independent of receptor blockade (e.g., RAS–MAPK, PI3K/AKT/mTOR), adaptive angiogenesis via VEGF-independent routes, and immune evasion through upregulation of checkpoint molecules such as PD-L1 [3, 4]. Therefore, patients ultimately present with progressive disease while on lenvatinib treatment. To expand the therapeutic potential of lenvatinib, there is an urgent need to identify biomarkers and novel targets for combination therapy that could support more durable responses for patients with advanced TC. In recent decades, it has become evident that the immune system plays an essential role in tumor pathogenesis and progression. Cells of the adaptive immune system have been therapeutically exploited, leading to clinical benefit in tumors that are positive for programmed death ligand 1 (PD-L1), have a high tumor mutational burden (TMB), or display microsatellite instability (MSI) [5]. However, the tumor microenvironment (TME) in advanced TC is highly infiltrated by tumor-associated macrophages (TAMs), myeloid cells of the innate immune system [6, 7]. TAMs promote tumor progression by secreting pro-tumorigenic cytokines and growth factors, reprogramming the metabolic landscape of the TME to favor cancer cell survival and facilitating tumor invasion and metastasis [8, 9]. Interestingly, an increased density of TAMs in the TME of TC patients has been demonstrated to be correlated with advanced disease and decreased survival [6]. Therefore, strategies aimed at reprogramming TAMs might be an interesting modality in the treatment of patients with advanced TC. A large proportion of TAMs are generated from circulating monocytes that are recruited to the tumor site, and further differentiate into TAMs under the influence of tumor-promoting factors present in the TME [8]. In addition, previous studies indicate that circulating monocytes from patients with malignant tumors recapitulate similar transcriptional and functional characteristics of the TAMs isolated from these tumors [10, 11]. It is therefore compelling to study the effects of lenvatinib on monocytes in the setting of advanced TC. Previous research has indicated that lenvatinib induces immunomodulatory properties on monocytes, including alterations in cytokine production, surface marker expression, and metabolic activity [12]. The same study reported that monocytes and macrophages were more susceptible to lenvatinib than lymphocytes and neutrophils, in an ex vivo setting. However, this study was performed in healthy donors, and immunological data in patients with advanced TC are lacking. The current study aims to investigate the immunomodulatory effects of lenvatinib in patients with advanced TC. We have established a cohort of patients with advanced TC treated with lenvatinib. This cohort was cross-sectionally compared with a cohort of patients with TC who had not yet received lenvatinib. Moreover, a second prospective cohort of patients with advanced TC that were initiated on lenvatinib treatment was established, which was assessed longitudinally before and after the initiation of lenvatinib treatment. Extensive immune profiling was performed, including ex vivo immune cell culture, cytokine production capacity assays, and plasma proteomics. We then expanded our study with mechanistic ex vivo and in vitro experiments to further investigate the functional effects of lenvatinib. This work is highly relevant for the understanding of the immunological effects of lenvatinib, with a particular emphasis on monocytes, and could contribute to the development of new therapeutic approaches for patients with TC. Materials and methods Patient selection Consecutive patients were included between December 2021 and January 2025 at the Radboud University Medical Center, Nijmegen, the Netherlands. All patients met the following inclusion criteria: advanced (locally unresectable or metastatic) and progressive TC, eligible for or using treatment with lenvatinib based on the clinical indication established by their treating physician, no prior TKI therapy for at least 3 months, no surgery for at least 3 months, and aged 18 years or older. Criteria for exclusion were: mental incompetence, pregnancy or breastfeeding, inflammatory or infectious comorbidities, or treatment with immunomodulating medication. For the mechanistic studies, healthy donors were included through our institution donor service. Study approval The study was approved by the local Ethics Committee (Commissie Mensgebonden Onderzoek Radboudumc: 2020-7123 for longitudinal study, 2022-16025 for cross-sectional study, NL84281.091.23 for healthy donors). All patients and healthy donors provided written informed consent, and all study procedures were conducted according to the principles of the Declaration of Helsinki. Study design The study was divided into three cohorts. The cross-sectional cohort compared immune cell function of patients who were receiving lenvatinib therapy for at least one month (n = 16), versus patients who did not receive lenvatinib (n = 15). The longitudinal cohort prospectively followed patients who were starting lenvatinib treatment (n = 8). Blood was collected before start of lenvatinib treatment, and after at least one month on lenvatinib therapy. The lenvatinib-naïve cohort (n = 23) was established by combining the control patients from the cross-sectional cohort and the baseline blood draw from the patients in the longitudinal cohort. We selected this cohort to study the ex vivo effects of lenvatinib, as none of these individuals had prior exposure to the drug. Radiological responses to lenvatinib were determined using RECIST 1.1 [13]. Blood sampling and immune cell isolation Blood was collected by venipuncture in ethylenediaminetetraacetic acid (EDTA) collection tubes. Plasma was obtained from blood by centrifugation and stored at -80 °C until further use. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation by layering whole blood on SepMate tubes (Stemcell Technologies) filled with Ficoll-Paque (Cytiva; Cat #17144003) and following manufacturer’s instruction. Monocytes were isolated from PBMCs by negative selection, using Pan Monocyte Isolation kit (Miltenyi Biotec; Cat #130-096-537), according to manufacturer’s instruction. Cells were counted using a Sysmex-XN 450 hematology analyzer (Sysmex). Immune cell culture and ex vivo stimulation Patient monocytes were cultured in serum-free RPMI (Life Technologies) supplemented with pyruvate (1 mM; Cat #11360070), GlutaMAX (2 mM; Cat #35050061), and gentamicin (50 µg/ml; Cat # 15750037) (All from Gibco). Patient PBMCs and healthy donors monocytes were cultured in similar medium with the addition of 10% human pooled serum (HPS). Patient monocytes were plated at a density of 1.5 × 105 monocytes/well in 96-well flat-bottom plates and cultured for 1 h to promote cell attachment. Monocytes were pre-stimulated with lenvatinib (Selleckchem; Cat #S1164) for 1 h using concentrations that are physiologically relevant (100 nM and 1 µM). Pharmacokinetic studies report Cmax ranges of approximately 260–420 ng/mL (≈0.6–1.0 µM) in subjects receiving the approved 24 mg daily dose [14, 15]. The selected range therefore allows coverage of clinically relevant concentrations. Escherichia coli-derived lipopolysaccharide (LPS; Sigma-Aldrich; serotype O55:B5; Cat #L6529) was added at 10 ng/mL to induce production of monocyte-derived cytokines. Patient monocytes were incubated with LPS only, LPS plus lenvatinib, or DMSO vehicle control, for 24 h. Patient monocyte experiments were performed in technical duplicate. Patient PBMCs were cultured at 5 × 105 PBMCs/well in 96-well round-bottom plates and stimulated for 7 days with 1 × 106 CFU of heat killed Staphylococcus Aureus (ATCC; Rosenbach 25,923), in duplicate, to induce production of lymphocyte-derived cytokines. Supernatant was collected and stored at − 20 °C until measurement. Olink proteomics Inflammatory markers were determined using the commercial Target 96 Inflammation panel of Olink Proteomics (Olink Bioscience; RRID:SCR_003899), according to the manufacturer’s instructions. Measurements were performed on an Olink Signature Q100 system, which measures 92 preselected inflammation-related proteins by multiplex proximity extension assays, as quantified by real-time PCR. Differential expression data were analyzed using the OlinkAnalyze R package. Olink proteomics was performed on patient plasma samples and on supernatant from lenvatinib-treated TPC-1 cell line. Cytokines ELISA Cytokine (TNF, IL-1Ra, IL-1β, IL-6, IL-8, IL-10, IL-17, and IFN-γ) concentrations in patient supernatants were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems; Cat #DY210, #DY280, #DY201, #DY206, #DY208, #DY217B, #DY317, and #DY285) following the instructions of the manufacturer. Absorbance measurements were performed using a BioTek 800 TS (Agilent Technologies; RRID:SCR_01972). Metabolic measurements Given that both tumor cells and myeloid cells frequently undergo metabolic reprogramming toward enhanced glycolysis [16, 17], we performed seahorse metabolic assays to measure the oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR), indicators of mitochondrial respiration and glycolytic activity, respectively. For seahorse experiments, monocytes from healthy donors (2 × 105 per well) were pre-incubated with 1 µM lenvatinib for 24 h as performed in a previous study [12]. Then, the monocytes were seeded onto overnight-calibrated cartridges in assay medium (DMEM (Gibco; Cat #11,965,092) supplemented with 1 mM of pyruvate, 2 mM of L-Glutamine (Gibco; Cat #25,030,081), and 1 mM of glucose (Sigma-Aldrich; Cat #G8644) for the Mito Stress Test; DMEM supplemented with 1 mM of L-Glutamine for the Glyco Stress Test, pH = 7.4), and incubated for 1 h in a non-CO2-corrected incubator at 37 °C. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were analyzed using the Mito Stress and Glyco Stress Test kit in a Seahorse XF96 analyzer (Agilent; RRID:SCR_02664). The Mito Stress Test was performed with sequential injections of mitochondrial respiration inhibitors at final concentrations of 1 µM of oligomycin (Cat #O4876), 1 µM of FCCP (Cat #C2920), 0.5 µM of Rotenone (Cat #R8875), and 0.5 µM of Antimycin A (Cat #A8674) (All from Sigma-Aldrich). The Glyco Stress Test was performed with 50 mM 2-DG (Sigma-Aldrich; Cat #D6134) in the presence of 10 mM glucose. Each condition was tested in quadruplicates. Monocytes from healthy donors (1 × 105 per well) were treated in duplicate with 1 µM lenvatinib for 24 h, after which relative ATP contents were assessed using CellTiter-Glo 2.0 (Promega, Cat #G9241) according to the manufacturer’s instructions. Lactate concentrations in patient supernatants were measured using Amplex Red Lactate Oxidase Assay. Briefly, standards or diluted samples were added to a black 96-well plate, followed by reaction mix containing Amplex Red (Invitrogen, Cat #A12222), 10 U/mL horseradish peroxidase (Sigma-Aldrich; Cat #P2088), and 100 U/mL lactate oxidase (Sigma-Aldrich; L9795), in PBS. After incubation in the dark for 20 min at room temperature, fluorescence was measured at 530 ± 25 nm excitation and 590 ± 35 nm emission. CellTiter-Glo 2.0 and Amplex Red Lactate Oxidase Assay were measured on a BioTek Synergy HTX multimode reader (Agilent Technologies; RRID:SCR_01974). ROS production Production of reactive oxygen species (ROS) has been linked to both pro- and anti-tumoral functions, making its role complex and context-dependent [18]. Monocytes from healthy donors (2 × 105 per well) were pre-incubated in duplicate with 1 µM lenvatinib for 24 h, in white opaque flat-bottomed 96-well plates. Reactive oxygen species (ROS) production was induced in lenvatinib-free medium using plasma-opsonized zymosan A (Sigma-Aldrich; Z4250) at a concentration of 1 mg/mL. Luminol (Sigma-Aldrich; Cat #A8511) was added with a final concentration of 0.1 mM, and chemiluminescence was measured at a wavelength of 425 nm every 142 s, for 1 h, on a BioTek Synergy HTX multimode reader. Phagocytosis assay Monocytes from healthy donors (1 × 105 per well) were pre-incubated with 1 µM lenvatinib for 24 h in duplicate. Phagocytic activity was assessed by incubation with 25 µg/mL pHrodo Green Zymosan Bioparticles (Sartorius; Cat #4618) in lenvatinib-free medium, according to the manufacturer’s instructions. Plates were immediately transferred to the Incucyte S3 live-cell analysis system (Sartorius; RRID:SCR_023147) and imaged every 15 min for a total of 2 h. TPC-1 cell culture and drug-related assays Tumor cells were cultured in RPMI 1640 medium with GlutaMAX supplement (Gibco; Cat #61870036), supplemented with 10% fetal calf serum (Capricorn; Cat #FBS26A) and 100 U/mL penicillin–streptomycin (Gibco; Cat #15140122). TPC-1 cells (RRID:CVCL_6298) were treated with 100 nM lenvatinib or DMSO control for 48 h, and supernatant was collected for proteomics. Images were acquired using a Leica DMi1-inverted microscope equipped with a 5 × objective and LAS v4.12 software (RRID:SCR_016555). For lenvatinib dose–response assay, 2 × 103 cells/well were seeded in white opaque flat-bottomed 96-well plates and allowed to attach overnight. Lenvatinib was added in triplicate, at six concentrations prepared by serial fourfold dilutions, starting from 10 µM, and incubated for 48 h. Cell metabolic activity was assessed by normalizing relative ATP contents to DMSO control, using CellTiter-Glo 2.0 according to the manufacturer’s instructions. Cytotoxicity was determined in supernatants from the dose–response experiment using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega; Cat # G1780). We normalized the results to the positive control digitonin (Sigma-Aldrich; Cat #D141). Both dose–response and cytotoxicity measurements were performed on a Synergy HTX multimode reader. Flow cytometry Tumor cells often impair antigen presentation and upregulate immune checkpoints to evade the immune system [19]. To assess surface marker expression, TPC-1 cells were incubated for 48 h with 100 nM lenvatinib in 96-well plates. Cells were detached using TrypLE (Gibco) and washed with PBA-EDTA (PBS supplemented with 1% BSA and 2 mM EDTA). Then, cells were stained using a panel consisting of: HLA-A,B,C-PE (Cat #311405; Clone W6/32; RRID:AB_314874), PD-L1-APC (Cat #393609; clone MIH2; RRID:AB_2749926), and CD40-BV421 (Cat #334331; Clone 5C3, RRID:AB_2564210) (all from Biolegend). After 30 min of staining at 4 °C, samples were measured on a CytoFLEX S flow cytometer (Beckman Coulter; RRID:SCR_027083). Data were analyzed using FlowJo version 10.8.1 (RRID:SCR_008520). Statistics Statistical analyses were performed with RStudio version 12.1 (RRID:SCR_000432) and Prism version 10 (GraphPad; RRID:SCR_002798). Baseline characteristics are presented as n (%) or as median (IQR). Nonparametric Wilcoxon signed-rank tests were used to compare paired data. For unpaired data, nonparametric Wilcoxon rank-sum tests were applied. Fisher’s exact test was used to compare the categorical data. Cell line flow cytometry data are analyzed by paired t-tests. Data are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Results Patient characteristics The schematic representation of the study cohorts and procedures is presented in Fig. 1A. Samples from the cross-sectional, longitudinal, and lenvatinib-naïve cohorts were used for downstream analyses. After measuring cell counts in whole blood (EDTA) and performing Olink proteomics on EDTA plasma, peripheral blood mononuclear cells (PBMCs) and monocytes were isolated and treated ex vivo, followed by profiling of inflammatory mediators. Graphical design of the study and immune cell counts in circulation. A Study design indicating the patient cohorts and study workflow. B Immune cell subset counts in EDTA blood of patients from the cross-sectional cohort (control n = 15, lenvatinib n = 16). Data represent mean ± SEM. C Immune cell subset counts in EDTA blood of patients from the longitudinal cohort. Shown are individual patients (n = 8). Wilcoxon signed-rank tests were used to compare paired samples and Wilcoxon rank-sum tests for unpaired samples At the time of inclusion, all patients had radiologically confirmed distant metastases and progressive disease (PD), according to RECIST 1.1 [13] (Table 1). All patients had stable disease (SD) or a partial response (PR) while blood was drawn on lenvatinib treatment. Most patients previously underwent a thyroidectomy and received radioactive iodine. In the cross-sectional cohort, clinical characteristics were generally comparable between the control and lenvatinib group, with no statistical significant differences with respect to age, sex, and BMI. The histological subtypes did vary slightly between the groups in the cross-sectional cohort, illustrated by a higher proportion of patients in the lenvatinib group diagnosed with papillary TC (56% vs 20%), and more patients with oncocytic TC in the control group (33% vs 6%). Five patients received sorafenib, another TKI, before starting lenvatinib therapy in the cross-sectional cohort. In the longitudinal cohort, six out of eight patients had a PR while blood was drawn on lenvatinib treatment. Table 1Clinical and demographic characteristics of the patient cohortsCharacteristicCS-control(n = 15)CS-lenvatinib(n = 16)P-value (CS)Longitudinal(n = 8)Lenvatinib-naïve(n = 23)Age (years)0.2677 Median (IQR)68 (65–76)67 (60–74)66 (59–73)67 (64–75)Sex, n (%)0.1556 Female10 (67)6 (37)4 (50)14 (61) Male5 (33)10 (62)4 (50)9 (39)BMI (kg/m2)0.2681 Median (IQR)31 (24–37)28 (25–30)29 (27–32)29 (26–33)Diagnosis at inclusion, n (%)N/A Papillary TC3 (20)9 (56)4 (50)7 (30) Follicular TC2 (13)2 (13)1 (13)3 (13) Oncocytic TC5 (33)1 (6)0 (0)5 (22) Poorly Differentiated TC5 (33)4 (25)3 (38)8 (35) M1 and progressive disease15 (100)16 (100)8 (100)23 (100)Previous treatments, n (%)N/A Thyroidectomy13 (87)14 (88)6 (75)19 (83) Radioactive iodine11 (73)14 (88)6 (75)18 (78) Radiotherapy4 (27)7 (44)4 (50)8 (35) Other TKI0 (0.0)5 (31)0 (0)0 (0)Lenvatinib administration Median duration, months (IQR)N/A3 (2–39)2 (2–3)N/A Median daily dose, mg (IQR)N/A14 (14–20)14 (13–24)N/AResponse on lenvatinib by RECIST, n (%) Progressive diseaseN/A0 (0)0 (0)N/A Stable diseaseN/A7 (44)2 (25)N/A Partial responseN/A9 (56)6 (75)N/ACS cross-sectional, IQR interquartile range, N/A not applicable, BMI body mass index, TC thyroid cancer, M1 distant metastases. P-values were calculated for the CS cohort using the Wilcoxon rank-sum test for BMI and age, and Fisher’s exact test for sex. PD, SD, and PR were determined per RECIST 1.1 Clinical and demographic characteristics of the patient cohorts CS cross-sectional, IQR interquartile range, N/A not applicable, BMI body mass index, TC thyroid cancer, M1 distant metastases. P-values were calculated for the CS cohort using the Wilcoxon rank-sum test for BMI and age, and Fisher’s exact test for sex. PD, SD, and PR were determined per RECIST 1.1 Lenvatinib treatment is associated with systemic elevation of lymphocyte counts and reduction of neutrophil counts We first studied the systemic effects of lenvatinib treatment on the absolute numbers of immune cell subsets in EDTA blood (Fig. 1B–C). In the cross-sectional cohort, the numbers of white blood cells (WBCs), lymphocytes, neutrophils, and monocytes did not differ significantly between control and lenvatinib-treated patients (Fig. 1B). However, in the longitudinal cohort, we observed that after lenvatinib treatment, absolute lymphocyte counts increased and neutrophils counts decreased compared to baseline (Fig. 1C). This general decrease in neutrophil-to-lymphocyte ratio (NLR) indicates modulation of immune subsets consistent with an adaptive immune response. The reduction in WBC numbers was observed as a trend and is likely caused by the reduction of absolute neutrophil count. In the longitudinal cohort, absolute monocyte counts remained unchanged. Lenvatinib treatment modulates the inflammatory proteome To further examine the systemic immunological effects of lenvatinib, we performed Olink proteomics on EDTA plasma (Fig. 2). Olink measured normalized protein expression (NPX) of 92 inflammation-related proteins in 15 cross-sectional control patients, 16 cross-sectional lenvatinib-treated patients, and seven longitudinal paired samples (one sample was excluded after quality control). Principal component analysis (PCA) was performed to reduce the dimensionality in the large dataset, with the aim to identify clusters of groups based on their protein expression. In the cross-sectional cohort, the first two principal components explained 30.8% (PC1) and 9.3% of the variance (PC2) (Fig. 2A). In the longitudinal cohort, PC1 captured 41.1%, and PC2 captured 11.4% of the variance. In both cohorts, PCA revealed partial separation of the samples based on treatment group, indicating some clustering as well as heterogeneity in the proteomic response, likely driven by individual variability. Systemic immunological profiling of lenvatinib by Olink plasma proteomics. A Principal component analysis (PCA) plot mapping PC1 and PC2 for cross-sectional (control n = 15, lenvatinib n = 16) and longitudinal (n = 7) cohorts. B Volcano plots depicting differential protein expression based on unadjusted p-values (threshold for significance indicated by dotted horizontal line). Blue proteins indicate a downregulation, and red proteins indicate an upregulation. C Boxplots of selected proteins with notable differential expression (unadjusted p-value < 0.05). The left panel indicates the cross-sectional cohort, and the right panel shows the longitudinal cohort. NPX: normalized protein expression. PC: principal component We performed differential protein expression analysis using Wilcoxon tests for each protein, followed by calculating fold changes based on NPX values. Volcano plots were generated using unadjusted p-values to visualize differential expression in both the cross-sectional and longitudinal cohorts. After multiple testing correction using the false discovery rate (FDR) method was applied, no proteins reached significance in the longitudinal cohort, likely due to the relatively small sample size. Therefore, volcano plots are presented based on unadjusted p-values for consistency across cohorts. Detailed Wilcoxon test results, including unadjusted p-values, fold changes, and FDR-adjusted p-values, are provided in supplementary material 1 and 2. In the cross-sectional cohort, 15 proteins were downregulated, and five proteins were upregulated, while 37 proteins showed upregulation in the longitudinal cohort (Fig. 2B). Several candidate proteins were consistently elevated in both cohorts during lenvatinib treatment, including vascular endothelial growth factor A (VEGFA), CC motif chemokine ligand 11 (CCL11), matrix metalloproteinase-10 (MMP-10), and TNF-related apoptosis-inducing ligand (TRAIL), indicating the consistent and significant upregulation of these treatment-associated biomarkers across both cohorts (unadjusted p-value < 0.05) (Fig. 2C). In the cross-sectional cohort, additional proteins latency-associated peptide transforming growth factor beta-1 (LAP TGF-beta-1) and sulfotransferase 1A1 (ST1A1) also showed notable differential expression. In the longitudinal cohort, interferon-gamma (IFN-γ) and tumor necrosis factor (TNF) were selected to illustrate key inflammatory markers that are upregulated upon lenvatinib treatment. These treatment-associated biomarkers highlight differences in protein expression between control and treatment groups, providing a clear visualization of the systemic immunological response to lenvatinib. Ex vivo lenvatinib treatment inhibits the capacity of monocytes to produce inflammatory mediators We next investigated the direct cellular responses to lenvatinib using ex vivo PBMC and monocyte culture models, which allowed us to dissect specific immune cell functions in a controlled setting. We treated monocytes with two physiologically relevant concentrations of lenvatinib (100 nM and 1000 nM), as reported in the previous work [12]. Production of monocyte-derived cytokines was induced by LPS stimulation and measured in supernatant by ELISA. Ex vivo lenvatinib exposure inhibited the capacity of patient-derived monocytes to produce cytokines IL-1β, IL-6, IL-8, and IL-10, in a dose-dependent manner (Fig. 3A). In addition, a modest but significant decrease was observed for TGF-β and lactate production. IL-1Ra and TNF production remained similar after lenvatinib stimulation. Lenvatinib treatment affects cytokine production in patient-derived monocytes and PBMCs. A Cytokine production in monocytes from patients in the lenvatinib-naïve cohort after exposure with ex vivo lenvatinib and LPS for 24 h (n = 23). B Cytokine production in monocytes from patients in the cross-sectional cohort after stimulation with LPS for 24 h (control n = 15, lenvatinib n = 16). C Cytokine production in PBMCs from patients in the cross-sectional cohort after stimulation with S. Aureus for 7 days. D Fold change in cytokine production in LPS-stimulated monocytes in patients from the longitudinal cohort, comparing cytokine production from while on lenvatinib treatment versus baseline and showing RECIST while on lenvatinib treatment (n = 8). Cytokines were measured by ELISA, and lactate concentrations were assessed with Amplex red oxidase assay. The bar graphs indicate mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 by Wilcoxon signed-rank test for paired data, or Wilcoxon rank-sum test for unpaired data. RFU: relative fluorescence units Lenvatinib treatment is associated with a higher production capacity of IL-1Ra, TNF, and IFN-γ We similarly isolated PBMCs and monocytes from patients in the cross-sectional cohort and stimulated the cells with S. Aureus and LPS, respectively (Fig. 3B–C). Here we compared the effects of in vivo lenvatinib treatment on cytokine production capacity. As opposed to the ex vivo lenvatinib stimulations, the concentrations of IL-1β, IL-6, IL-8, and IL-10 were not significantly different between the lenvatinib-treated and control patients from the cross-sectional cohort (Fig. 3B). However, we observed that monocytes from lenvatinib-treated patients had an increased capacity to produce cytokines IL-1Ra and TNF. Furthermore, PBMCs of lenvatinib-treated patients were associated with a higher production capacity of IFN-γ and showed a trend toward an increased production of IL-17 (p = 0.0986) (Fig. 3C). We also measured cytokines in the supernatant of LPS-stimulated monocytes from the longitudinal cohort. No cytokines were significantly altered during lenvatinib treatment, which may be attributed to high individual variability and our relatively low sample size, as illustrated in the heatmap (Fig. 3D). Lenvatinib treatment decreases glycolysis, increases ROS production, and has no effect on phagocytosis in monocytes of healthy donors We expanded our study to assess the functional effects of lenvatinib on monocytes, specifically examining cellular metabolism, reactive oxygen species (ROS) production, and phagocytic capacity. Lenvatinib-treated monocytes showed a trend toward reduced mitochondrial respiration, while all glycolytic parameters were significantly downregulated (Fig. 4A). This reduction in glycolytic function is consistent with the decreased lactate production that we observed in patient-derived monocytes after ex vivo exposure to lenvatinib, as the main product of glycolysis is lactate (Fig. 3A). We examined ROS production in monocytes following zymosan stimulation (Fig. 4B). Interestingly, ROS levels were elevated in lenvatinib-treated monocytes compared to DMSO control. Since ROS production usually follows after phagocytosis, we assessed the phagocytic activity of zymosan-stimulated monocytes (Fig. 4C). In contrast, we observed no significant differences in phagocytosis between conditions, although donor variability was considerable. To exclude the possibility that ex vivo lenvatinib treatment reduced absolute monocyte numbers, and thereby causing decreased glycolytic rates, or a general decreased cytokine production in patient-derived monocyte experiments, we performed a CellTiter-Glo assay. No decrease in luminescent signal was observed, indicating that lenvatinib treatment did not reduce absolute monocytes numbers (Supplementary Fig. 1A). Functional impact of lenvatinib on monocyte metabolism, ROS production, and phagocytic capacity in healthy donors. A Seahorse analysis in monocytes from healthy donors that were pre-incubated with ex vivo lenvatinib for 24 h (n = 8). The upper panels show OCR and ECAR kinetics from all donors combined, and the lower panels show the specific metabolic parameters that were calculated per donor. OCR: oxygen consumption rate, ECAR: extracellular acidification rate. B Zymosan-induced ROS production (n = 9). The left panel shows the kinetics from all donors combined, and the right panel the AUC from single donors. C Zymosan-induced phagocytic activity (n = 5). The left panel shows the kinetics from all donors combined, and the right panel the AUC from single donors. * p < 0.05 by Wilcoxon signed-rank test. RLU: relative light units, GCU: green calibrated units Lenvatinib modulates the secretome and immune marker expression in TPC-1 tumor cells To assess whether the immunomodulatory effects extended beyond immune cells, our final set of experiments was performed on the TC cell line TPC-1, which harbors a CCDC6-RET gene fusion that renders it sensitive to lenvatinib. First, we studied the effects of lenvatinib on cell morphology and cell growth (Fig. 5A–B). Lenvatinib treatment induced a morphological shift in tumor cells, with cells appearing more flattened and enlarged (Fig. 5A). We assessed the growth inhibiting effects of lenvatinib by dose–response assay and used a concentration of 100 nM (IC20–IC30) for subsequent experiments (Fig. 5B). Lenvatinib alters cell morphology, secretome, and surface marker expression on TPC-1 tumor cells. A Light microscopy pictures after incubating TPC-1 cells with 100 nM lenvatinib for 48 h. Scale bar represents 1000 µm. B Dose–response assay of lenvatinib by CellTiter-Glo assay. Values are normalized to DMSO control. The vertical line indicates 100 nM that was selected for functional experiments. The curves represent data from two biological replicates. C Olink proteomics on supernatant. The horizontal dotted lines indicate the upper and lower 50% thresholds. D Flow cytometry surface marker staining for MHC-I, PD-L1, and CD40. Data are shown from five biological replicates. * p < 0.05 by paired t-test. MFI: median fluorescence intensity We then performed Olink proteomics on the supernatant of lenvatinib-stimulated TPC-1 cells. Fold changes were calculated based on NPX values, and the cutoff was set at a 50% increase or decrease compared to DMSO control. We observed that lenvatinib treatment highly affects the secretome of the TPC-1 cell line, indicated by 18 proteins that were upregulated, and ten proteins that were downregulated (Fig. 5C). Interestingly, CCL-11 was also found to be elevated in both cross-sectional and longitudinal cohorts (Fig. 2C). This mediator could therefore originate from tumor cells, although further validation is needed. Additionally, IFN-γ and CCL19 were upregulated both in the longitudinal patient cohort and in the TPC-1 cell line. To assess the effects of lenvatinib on surface marker expression of the TC cells, flow cytometry was performed. Notably, lenvatinib increased surface expression of MHC class I, PD-L1, and CD40, which could be involved in the modulation of immune responses (Fig. 5D). We also performed an LDH assay to exclude the possibility that lenvatinib-induced effects were due to cell stress or severe cytotoxicity. No increase in cytotoxicity was observed in lenvatinib-treated TPC-1 cells, even at a higher concentration of 10 μM (Supplementary Fig. 1B). Discussion The current study demonstrates that lenvatinib has a wide range of immunomodulatory properties in patients with advanced TC. These functional effects were investigated across multiple biological compartments, including circulation, ex vivo immune cells, and in a tumor cell line. Our findings suggest that the immune-related effects of lenvatinib may enhance its therapeutic efficacy and warrant further exploration in the context of biomarker development and combination therapy strategies. We observed that lenvatinib treatment is associated with an increase in absolute lymphocyte numbers and a decrease in absolute neutrophil cell counts, which indicates a general decrease in NLR and activation of the adaptive immune system. Earlier work has confirmed that lenvatinib increases specifically cytotoxic T lymphocytes counts in patients with hepatocellular carcinoma (HCC) [20]. In addition, previous studies in non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) have indicated that a decrease in NLR often occurs during clinical responses, and was associated with favorable survival rates toward TKIs or ICIs [21, 22]. In our study, all patients had a SD or PR at the time of blood collection while on lenvatinib. These findings suggest that the decrease in NLR may serve as a potential on-treatment biomarker of response to lenvatinib, although further validation in larger cohorts is needed. Interestingly, in the cross-sectional cohort, immune cell counts did not differ between control and lenvatinib-treated patients, which may reflect interpatient variability or differences in prior TKI exposure. The current study highlights that the inflammatory proteome is extensively altered during lenvatinib treatment, supporting its dual role as a targeted therapy and immune modulator. We identified several potential treatment-associated biomarkers that were upregulated in both patient cohorts, including VEGFA, CCL11, MMP-10, and TRAIL. The increase in VEGFA is particularly interesting given that lenvatinib targets VEGF receptors as part of its anti-angiogenic nature. This upregulation likely reflects a compensatory feedback response to VEGFR blockade, rather than ongoing angiogenesis [23]. Another marker that was upregulated in both patients cohorts is CCL11, a chemokine with a pro-tumoral role that is involved in tumor migration and invasion [24]. The fact that all patients in our study had stable disease or a partial response does not imply that the elevated CCL11 levels reflect tumor progression, but could instead represent a tumor-intrinsic feedback mechanism triggered by lenvatinib treatment. Interestingly, we confirmed an upregulation of CCL11 after stimulating TPC-1 cells with lenvatinib, which indicates that tumor cells might play a dominant role in the production of CCL11. Similarly, MMP-10 is a mediator that is often upregulated across several tumor types and is generally involved in tumor progression [25]. Its upregulation may also reflect a compensatory mechanism to facilitate tumor adaptation under TKI treatment. Finally, TRAIL is another noteworthy protein that was upregulated. TRAIL induces apoptosis, specifically in tumor cells, while healthy cells are not targeted [26]. This upregulation could therefore indicate an enhancement of anti-tumoral immune responses during lenvatinib therapy. Notably, all patients in our study had a SD or PR during lenvatinib treatment, in line with the previous reports that most patients initially show a clinical response to lenvatinib treatment [2]. Therefore, future studies are warranted that include patients whose disease progresses during lenvatinib treatment to fully understand the role of these treatment-associated biomarkers. Taken together, these candidate markers indicate the complex tumor-immune system interplay when on lenvatinib treatment and should be further explored for their potential clinical use in monitoring treatment efficacy and possible resistance. While these systemic effects are likely caused by an interplay between multiple cell types, we were also interested in the immunomodulatory effects of lenvatinib in a controlled ex vivo setting. Results from cytokine profiling demonstrated a reduction of production capacity for cytokines IL-1β, IL-6, IL-8, and IL-10. The role of these cytokines in the TME remains complex, and most cytokines have pleiotropic effects depending on the tumor type, disease stage, and immune status [27–29]. However, it is indicated that the IL-6 axis is highly activated in patients with solid tumors and promotes tumor cell survival and cell proliferation [29]. This was also confirmed for patients with papillary TC [30]. On top of that, the reduction in IL-6 is in line with a previous study from our group that performed a similar experiment on macrophages generated from healthy donors [12]. Therefore, the inhibitory capacity of lenvatinib for IL-6 production could represent an anti-tumoral immunological effect. IL-8 has also been linked to pro-tumoral activities. To illustrate, clinical studies have demonstrated that myeloid-derived IL-8 contributes to resistance against ICI and that IL-8 can predict clinical outcomes to ICI therapy [31, 32]. In addition, IL-1β has primarily pro-tumoral roles by enhancing tumor cell proliferation and angiogenesis [28]. Furthermore, a study in pancreatic cancer has shown that high serum levels of IL-6, IL-8, and IL-10 are strongly associated with poor survival [33]. We therefore hypothesize that the broad inhibitory effect of lenvatinib on myeloid cells could potentially be translated toward a reversal of the immunosuppressed state of TAMs within the TME. Next to a decreased production capacity of tumor-promoting cytokines mentioned above, we found that lenvatinib treatment is associated with an increase in production capacity of IL-1Ra and TNF in patient-derived monocytes, and IFN-γ in PBMCs from patients in our cross-sectional cohort that were treated with lenvatinib in vivo. IL-1Ra blocks IL-1 from binding to its receptor, thereby inhibiting IL-1 mediated signaling, which is known to be highly carcinogenic [34]. TNF and IFN-γ are known to trigger apoptosis in recipient cells, which renders them suitable anti-tumoral mediators [35]. Furthermore, we noted a proteomic increase of TNF and IFN-γ levels in the longitudinal cohort, further supporting the potential anti-tumoral roles of these two cytokines. Thus, lenvatinib treatment could potentially result in production of more anti-tumoral mediators within the TME, potentiating its therapeutic efficacy. TAMs undergo functional and metabolic reprogramming during tumor progression [16, 17]. We found that ex vivo lenvatinib stimulation inhibited glycolytic function in monocytes, which also correlated with our previous study that was performed in macrophages [12]. In parallel, ROS production was elevated upon ex vivo treatment with lenvatinib. ROS can have dual roles within the TME, although it has been implied that increased ROS levels during TKI therapy can be lethal to tumor cells [36]. These findings support a role for lenvatinib in modulating cellular metabolism and ROS production, potentially attenuating the phenotype of myeloid cells toward a more tumor-suppressive state. Since most patients eventually develop resistance to lenvatinib treatment, there is an urgent need for rational combination therapies with other immune modulating agents. Tumors often downregulate the antigen presentation machinery and upregulate immune checkpoints to escape attack by immune cells, or become resistant to TKI therapy [4, 37]. We confirm that lenvatinib elevates surface marker expression of MHC class I in tumor cells, potentially enhancing tumor visibility to cytotoxic T cells. Lenvatinib additionally increased CD40 expression, which is classically associated with antigen-presenting cells. CD40 expression on tumor cells has been linked to enhanced immunogenicity and increased susceptibility to T cell-mediated cytotoxicity [38, 39]. Consistent with this immunomodulatory profile, we also observed an increased PD-L1 expression on tumor cells, a hallmark of adaptive immune resistance. The findings in our study further support the notion that ICIs represent a promising conventional therapy to be combined with lenvatinib. As such, lenvatinib has been clinically tested in combination with the anti-PD-1 antibody pembrolizumab in patients with differentiated, poorly differentiated, and anaplastic TC [40, 41]. Although encouraging results, larger clinical studies are yet to be established in the context of advanced TC. Interestingly, phase 3 trials in advanced RCC and endometrial cancer have shown that the combination of lenvatinib plus pembrolizumab resulted in significantly longer PFS compared to standard of care [42, 43]. We therefore hypothesize that lenvatinib could also increase the clinical benefit when combined with ICIs for the treatment of patients with advanced TC. Our study has several limitations. First, we employed a number of ex vivo models to study the immunomodulatory effects of lenvatinib, which do not fully recapitulate the complexity of the TME. While in vivo models would allow for deeper mechanistic insights, this was not feasible in the current study. Nevertheless, by using a multi-compartment approach by a combination of circulating patient material, patient-derived monocytes, and a tumor cell line, we were able to capture key aspects of lenvatinib-induced immunomodulation. Another limitation was the relatively small sample size, particularly in the longitudinal cohort. Although patient numbers were limited, we observed that lenvatinib had consistent effects in peripheral blood in these patients. Due to the small sample size, formal assessment of potential differences in biological effects by histological subtype or by clinical response to lenvatinib was not possible. Finally, because only limited patient material could be obtained, some functional assays had to be performed using cells from healthy donors. These experiments should ideally be repeated in patient-derived samples in the future studies. In conclusion, this study demonstrates that lenvatinib has a broad range of immunomodulatory effects in patients with advanced TC. These findings have important translational implications for the biological effects of lenvatinib on the TME, biomarker discovery, and the development of combination therapies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (XLSX 11 KB) Supplementary file2 (XLSX 10 KB) Supplementary file3 (DOCX 44 KB) Acknowledgements The authors would like to acknowledge Heidi Lemmers, Helga Dijkstra, and Andrei Sarlea for their support in the laboratory. Author’s contributions RTN-M did the conceptualization, PC, CP, PvH, LvE, JEWW, PBO, MJ, and RTN-M developed the methodology, PC, CP, PvH, JEWW, PBO, MJ, and LvE participated in the investigation, PC, CP, and PvH did the analysis, PC participated in the writing—original draft, PC, CP, PvH, LvE, JEWW, PBO, MJ, and RTN-M did the writing—review and editing, PBO, MJ, and RTN-M did the supervision, and PC, CP, PvH, MJ, and RTN-M participated in the project administration. Funding This investigator-initiated research was funded by an unrestricted research grant from EISAI Co. Data availability All data generated or analysed during this study are included in this published article (and its supplementary information files). Additional datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Conflict of interest The authors declare no conflict of interest. Ethics approval The study was approved by the local Ethics Committee (Commissie Mensgebonden Onderzoek Arnhem-Nijmegen: 2020-7123 for longitudinal patients, 2022-16025 for cross-sectional patients, NL84281.091.23 for healthy donors). All donors provided written informed consent, and all study procedures were conducted according to the principles of the Declaration of Helsinki. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary file1 (XLSX 11 KB) Supplementary file2 (XLSX 10 KB) Supplementary file3 (DOCX 44 KB) Data Availability Statement All data generated or analysed during this study are included in this published article (and its supplementary information files). Additional datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.